Up next

Supplier News: Catalent, Rovi, Veranova, Aptar, Rezon Bio, Ansa Biotechnologies & NextPharma 

The latest from CDMOs, CMOs, and suppliers featuring Catalent, Laboratorios Farmacéuticos Rovi, Veranova, Aptar, Rezon Bio, Ansa Biotechnologies and NextPharma.  

General 
* Catalent Opens New Global HQ in Tampa, Florida
Biologics Manufacturing 
* Polpharma Biologics’ Spin-off Rezon Bio Launches as New CDMO
* Ansa Biotechnologies Secures $54 M in Financing for DNA Synthesis Platform 
Formulation Development/Drug Product Manufacturing 
* Rovi To Acquire BMS’ Injectable Drug-Product Mfg Facility
Packaging 
* Aptar Pharma Opens Expanded R&D Center in France 
Appointments 
* Veranova Names Ex-Catalent Executive as Sr. VP, COO 
* NextPharma Appoints New CEO  

General 

Catalent Opens New Global HQ in Tampa, Florida 
Catalent has opened a new global corporate headquarters in Tampa, Florida, following the relocation of its global headquarters from Somerset, New Jersey.  

Earlier this year (2025), Catalent announced it would relocate from its previous headquarters in Somerset, New Jersey,and open a corporate office in Bridgewater, New Jersey, and a new corporate headquarters in Tampa. The move to Tampa reflects a strategic expansion in Florida, where the company has a presence through its 500,0000-square-foot site in St. Petersburg, which has more than 630 employees and serves as the company’s primary softgel development and manufacturing facility in North America. 

The relocation of the company’s headquarters to Tampa also follows the $16.5-billion acquisition of Catalent by Novo Holdings, the parent entity of Novo Nordisk, in December 2024. Novo Holdings later sold three Catalent fill–finish sites (Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium) and related assets to Novo Nordisk for $11 billion to increase Novo Nordisk’s manufacturing capacity for its GLP-1 agonists and other products. The Catalent acquisition is increasing Novo Nordisk’s filling capacity from 2026 and onwards. 

Source: Catalent 

Biologics Manufacturing 

Polpharma Biologics’ Spin-off Rezon Bio Launches as New CDMO 
Rezon Bio has launched as a CDMO of biologics. Based in Poland with two facilities in Gdańsk and Warsaw-Duchnice, the company specializes in mammalian drug-substance development and GMP manufacturing. The company was demerged from Polpharma Biologics, which spun off its biologics CDMO business in forming Rezon Bio. Polpharma Biologics will continue to operate its biosimilars business out of Switzerland, under the original brand – Polpharma Biologics.  

Source: Rezon Bio and Polpharma Biologics 

Ansa Biotechnologies Secures $54 M in Financing for DNA Synthesis Platform 
Ansa Biotechnologies, a DNA synthesis company, has announced that it has secured $54.2 million in financing by closing $45.2 million and securing commitments for an additional $9.2 million as part of an oversubscribed Series B financing round. The company says that proceeds from this financing will be used to expand its US-based manufacturing capacity and introduce applications, among other uses. The company has a proprietary enzymatic platform for making complex DNA sequences in both clonal DNA or linear double-stranded DNA fragment formats. 

The financing round was led by Cerberus Ventures with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and other existing investors. New investors include Fall Line Capital, AIM13, and Black Opal Ventures. As part of the financing, Chenny Zhang, Director at Cerberus Ventures, and Yanniv Dorone, PhD, Senior Vice President at Fall Line Capital, joined Ansa’s Board of Directors. 

Source: Ansa Biotechnologies 

Formulation Development/Drug Product Manufacturing 

Rovi To Acquire BMS’ Injectable Drug-Product Mfg Facility 
Laboratorios Farmacéuticos Rovi, a CDMO and bio/pharmaceutical company, has agreed to acquire Bristol Myers Squibb’s (BMS) injectable drug-product manufacturing facility in Phoenix, Arizona. As part of the acquisition, Rovi has entered into a toll manufacturing agreement with BMS, which regulates the conditions under which Rovi will continue to manufacture products for BMS at the facility. The agreement has an initial term of five years from the closing of the transaction and provides for a minimum payment of $50 million for each year of the contract. The completion of the transaction is expected to take place during the first half of 2026. 

Source: Laboratorios Farmacéuticos Rovi 

Packaging 

Aptar Pharma Opens Expanded R&D Center in France 
Aptar Pharma, a contract provider of drug-delivery and active material science products and services, has opened its new expanded R&D center in Le Vaudreuil and Val-de-Reuil, France, which increases research and development capabilities across Aptar Pharma’s proprietary drug-delivery business. 

The new R&D Center is on the site of Aptar’s Le Vaudreuil and Val-de-Reuil manufacturing sites in France, and is one of AptarGroup’s 11 global innovation centers. Fully operational since July 2025, Aptar Pharma’s new 3,000-square-meter (32,000-square-foot) R&D center houses 170 employees.  

Source:  Aptar Pharma 

Appointments 

NextPharma Appoints New CEO 
NextPharma, a London-based CDMO, has announced the appointment of Ajeeth Enjeti, current General Manager and President at Trivium Packaging, as CEO, succeeding Peter Burema, who is retiring and who has led the company as CEO since 2014. Enjeti will take up his new position on November 1, 2025. 

Having reached retirement, Burema will step down from the role of CEO and take up a position as Non-Executive Director on the Board of NextPharma in January 2026. Enjeti has served as General Manager and President at Trivium Packaging since 2021. Prior to that, he was Senior Vice President of Strategy and Transformation and member of the Executive Committee at Elementis, a specialty chemicals company, and has held a number of other senior positions with companies such as Mondo Minerals, Bain & Co., IBM, and PepsiCo.  

Source: NextPharma 

Veranova Names Ex-Catalent Executive as Sr. VP, COO 
Veranova, a CDMO of small-molecule active pharmaceutical ingredients and intermediate, has appointed Joe Torres-Ocasio, formerly Vice President of Global Operations for Catalent’s Biologics Division, as Senior Vice President and Chief Operating Officer (COO). In his role, Torres-Ocasio will lead Veranova’s global operations across its manufacturing network in Europe and North America and will also oversee the company’s Engineering, Environmental Health & Safety (EHS), and Supply Chain/Operational Excellence functions. 

In addition to serving as Vice President of Global Operations for Catalent’s Biologics Division, his career also includes leadership roles at Baxter Healthcare International, where he led the turnaround and growth of critical sites before becoming a regional Vice President. He began his career at Amgen as a manufacturing leader, where he led a high-impact Lean transformation. He later held senior operational roles at Immucor and Therapeutic Proteins International.  

Source: Veranova